Regeneron Pharmaceuticals (REGN) Revenue & Quarterly History
Explore Regeneron Pharmaceuticals, Inc. (REGN) revenue from 2023 through the latest reported quarter, with SEC-sourced comparisons and filing-constrained analysis.
Key takeaway
Quarter ended Mar 31, 2026 · FY2026 Q1
Revenue declined from the prior quarter but rose compared to the same quarter last year. The sequential decrease followed three consecutive quarters of growth.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$3.6B
Revenue reported for this quarter.
Quarter-over-quarter
-7.2%
Change from the immediately preceding quarter.
Year-over-year
+19.0%
Change from the comparable year-ago quarter.
Trailing four quarters
$14.9B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2025 | $3.7B | +3.6% |
| Sep 30, 2025 | $3.8B | +0.9% |
| Dec 31, 2025 | $3.9B | +2.5% |
| Mar 31, 2026 | $3.6B | +19.0% |
Revenue performance
Reported revenue moved lower from the immediately preceding quarter, reversing the prior upward trend.
Quarterly comparison
Compared with the same quarter one year earlier, revenue was higher. The sequential decline contrasts with the year-over-year increase.
What to watch
The filing context does not provide a specific explanation for the revenue change.